WCG
AMRX icon

Weaver Consulting Group’s Amneal Pharmaceuticals AMRX Stock Holding History

Weaver Consulting Group’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-18
Closed – – 172
2020
Q3 		$0 Hold
18
– – ﹤0.01% 958
2020
Q2 		$0 Hold
18
– – ﹤0.01% 933
2020
Q1 		$0 Hold
18
– – ﹤0.01% 839
2019
Q4 		$0 Hold
18
– – ﹤0.01% 836
2019
Q3 		$0 Hold
18
– – ﹤0.01% 823
2019
Q2 		$0 Buy
+18
New +$184 ﹤0.01% 812

Other funds holding AMRX

FI
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Weaver Consulting Group's AMRX Position: Q4 2020 in Review

Weaver Consulting Group sold out of Amneal Pharmaceuticals (AMRX) in Q4 2020, closing a stake of 18 shares.

Weaver Consulting Group first reported a position in AMRX in Q2 2019 and held it in 6 quarters. The position peaked at $0 in Q3 2020. 133 funds tracked by Wall St. Rank hold AMRX as of Q4 2020.

  • Weaver Consulting Group reported no remaining Amneal Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Weaver Consulting Group sold 18 Amneal Pharmaceuticals shares in Q4 2020.
  • Weaver Consulting Group first reported a position in Amneal Pharmaceuticals in Q2 2019 and held it in 6 quarters.
  • Weaver Consulting Group's Amneal Pharmaceuticals position peaked at $0 in Q3 2020.
  • 133 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q4 2020.

Based on Weaver Consulting Group's 13F filing for Q4 2020, filed 29 Jan 2021.